Results for tag: "Persistent Epithelial Defect Drug"

The Persistent Epithelial Defect Drug market is a subset of the Optical Disorders Drugs market. It is composed of drugs used to treat persistent epithelial defects, which are non-healing corneal ulcers that can lead to vision loss. These drugs are typically used to reduce inflammation, promote healing, and reduce the risk of infection. Commonly used drugs include antibiotics, antivirals, antifungals, and corticosteroids. In some cases, surgery may be necessary to repair the defect. The Persistent Epithelial Defect Drug market is highly competitive, with many companies offering products to treat these conditions. Some of the major players in the market include Allergan, Bausch + Lomb, Novartis, Santen, and Shire. Other companies such as Alcon, Merck, and Pfizer also offer products in this market. Show Less Read more